The field of antibody therapeutics has evolved dramatically, moving beyond traditional monoclonal antibodies to encompass advanced modalities such as antibody-drug conjugates (ADCs), bispecific antibodies, and other innovative constructs. Interest and investment have surged in these modalities to build a robust pipeline of novel antibody therapeutics from R&D to the clinic. These next-generation therapies hold immense promise, offering highly targeted and effective treatment options for complex diseases, from cancer to autoimmune conditions. However, their unique potential comes with equally unique challenges, including intricate design and development processes, manufacturing complexities, and the need for specialized expertise.
In this article, we'll explore the key considerations developers must navigate in bringing these sophisticated therapeutics to market. We'll also discuss how partnering with specialized suppliers can provide the expertise and technical capabilities necessary to overcome these hurdles and unlock the full therapeutic potential of novel antibody therapies.
Powerful possibilities for therapeutic antibodies
Recombinant antibody technology has opened the door to nearly infinite engineering possibilities for therapeutic antibodies. Amidst this vast potential, two promising new approaches to therapeutic antibody design stand out: multispecific antibodies and ADCs. Multispecifics bind multiple target antigens or epitopes simultaneously, either on the same or different cells. This dual targeting allows them to engage multiple pathways or recruit select immune cells to the site of action. While many researchers working to develop multispecific drugs may have the sequence of their desired antibody, it often takes deep and specialized expertise to perform sophisticated recombinant antibody engineering. By working with a partner specializing in recombinant antibody engineering, researchers can access valuable guidance in optimizing the configuration and properties of their drug candidate.
Search Recombinant antibodies Search Now Search our directory to find the right recombinant antibody for your research needs.
Bispecific and monospecific antibodies may also be used to form ADCs, in which the antibody is tethered to a drug payload by a linker. With ADCs, the antibody binds to a molecular target within the body, delivering the drug payload precisely to the tissue that requires therapeutic intervention. The linker between the two plays a complex and critical role beyond simply bringing the antibody and payload together. When engineered properly, the linker can aid in optimizing solubility, specificity, and manufacturability, ultimately yielding better ADC candidates.
Fine-tuning linker design for optimal performance
The linker is not just a bridge between antibody and drug payload—it plays a key role in the drug's function, influencing both safety and efficacy. It takes a deep understanding of biological chemistry to understand how linker parameters may be fine-tuned to improve the drug's efficacy while minimizing off-target effects. Thanks to several decades of research, scientists better understand the many ways to manipulate specific linker characteristics to optimize performance.
Among the key qualities a linker should have is a structure that promotes ADC stability in the blood plasma to prevent premature payload release in the body. It also should counteract the hydrophobicity common to most drug payloads, reducing aggregation and improving solubility. Several variations on linker design can achieve these two goals, including using either a cleavable or non-cleavable linker for payload release and making the linker more hydrophilic. This can be achieved, for example, by adding highly polar polyethylene glycol (PEG), polyhydroxyl, polycarboxyl, or sulfonate functional groups. Crucially, researchers must consider the parameters of ADC components holistically to optimize functionality without sacrificing key traits.
A significant challenge in ADC production is that the conjugation process linking the ADC components can often lead to a heterogeneous product. Therefore, selecting a linker that can conjugate to create consistent ADC molecules when manufacturing at scale is vital. With many design factors to consider, it’s challenging to leverage the full potential of linkers without deep, specialized expertise, which can be difficult for many groups to source in-house. Working with a partner specializing in ADC design can help drugmakers overcome challenges and unlock the full potential of their linkers, de-risking development, saving resources, and accelerating timelines.
Challenges in manufacturing
Recombinant antibody technology offers transformative improvements over the limited efficiency, consistency, and reliability of hybridoma-based antibody production. Scientists can now manufacture antibodies at any scale according to precise specifications using custom or off-the-shelf designs that they can readily modify. Yet, manufacturing challenges remain. Many organizations lack the specialized infrastructure needed for efficient production and purification of antibodies and linkers, and building this infrastructure takes a massive capital investment.
For these reasons, researchers at every level may benefit from leveraging antibody suppliers' expertise and resources to maximize the full potential of this powerful technology. Collaborating with a reliable antibody supply partner can secure access to a steady and efficient source of high-quality antibodies, spanning from discovery to clinical-scale production. These partners are often well-equipped to manufacture consistent batches of recombinant antibodies at scale, ensuring robust testing and adherence to regulatory standards from early development to commercial production. Contract development and manufacturing organizations (CDMOs) also provide valuable insights into the manufacturability of potential antibody therapeutics, helping to focus early-stage drug development on candidates that are feasible for large-scale production.
Looking to the future of antibody therapeutics
Therapeutic antibodies have been a fundamental medicinal approach for decades, providing a revolutionary way to treat disease. Now, the future of therapeutic antibodies lies in leveraging new configurations, such as bispecifics and ADCs made using recombinant antibody technology.
By partnering with recombinant antibody suppliers, companies large and small can rapidly acquire different antibody candidates during drug discovery, manufacture reliable, validated antibodies at scale, and even "resurrect" antibodies from hybridoma-generated cell lines that have undergone genetic drift. Together, researchers and specialized suppliers of linkers and recombinant antibodies can produce antibody therapeutics with transformative potential to address even the most difficult-to-treat diseases. Advances made will empower biomedical research, facilitating breakthroughs that may help address present global health challenges and prepare us to navigate those that arise in the future.
Catherine Bladen, Ph.D., is Vice President, Regional Executive and Principal Advisor, and Pamela James, Ph.D., is Vice President, Business Operations, at Vector Laboratories